Vertex Pharma (NASDAQ: VRTX) reported Q4 EPS of $3.79, $0.26 better than the analyst estimate of $3.53. Revenue for the quarter came in at $2.3 billion versus the consensus estimate of $2.3 billion.

GUIDANCE:

Vertex Pharma sees Q1 2023 revenue of $9.55-9.7 billion, versus the consensus of $9.6 billion.

For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.